Filing Flows › Pacira BioSciences (PCRX) › How it makes money
How Pacira BioSciences (PCRX) makes money
Pacira BioSciences (PCRX) made $177M of revenue in the third quarter 2026 (Q3 2026), -0.8% from a year earlier. Net product sales brought in $175M (99%); Bupivacaine liposome injectable suspension brought in $1.2M (1%). Of every dollar of revenue, 13¢ was left as operating profit, 16¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Net product sales | $175M | 99.3% | — | +0.1% |
| ↳ EXPAREL | $143M | 80.7% | — | +2% |
| ↳ ZILRETTA | $29.8M | 16.8% | — | +3% |
| ↳ iovera° | $2.0M | 1.1% | — | -69% |
| ↳ Service | $1.2M | 0.7% | — | — |
| Bupivacaine liposome injectable suspension | $1.2M | 0.7% | — | -56% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $177M | 100.0% |
| Operating profit | $22.3M | 12.6% |
| Income tax | $293K | 0.2% |
| Net earnings | $28.5M | 16.1% |
| Operating cash flow | $50.1M | 28.3% |
| Free cash flow | $46.4M | 26.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $177M | -2% |
| Q2 2026 | $192M | +6% |
| Q1 2026 | $177M | +5% |
| Q4 2025 | $197M | +5% |
| Q3 2025 | $180M | +6% |
| Q2 2025 | $181M | +2% |
| Q1 2025 | $169M | +1% |
From Pacira BioSciences' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Pacira BioSciences make money?
Pacira BioSciences (PCRX) made $177M of revenue in the third quarter 2026 (Q3 2026), -0.8% from a year earlier. Net product sales brought in $175M (99%); Bupivacaine liposome injectable suspension brought in $1.2M (1%). Of every dollar of revenue, 13¢ was left as operating profit, 16¢ was left as net earnings.
What is Pacira BioSciences' biggest business?
Net product sales: $175M in the third quarter 2026, 99% of revenue, +0.1% from a year earlier.
What is Pacira BioSciences' profit margin?
Net earnings were $28.5M, 16.1% of revenue, in the third quarter 2026; the operating margin was 12.6%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.